Healthcare stocks were edging higher premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2% and the iShares Biotechnology ETF (IBB) 0.6% higher.
Precigen (PGEN) shares were up more than 3% after the company said the US Food and Drug Administration granted orphan drug exclusivity for its recurrent respiratory papillomatosis treatment called papzimeos.
Zymeworks' (ZYME) drug to treat certain reproductive tract cancers has shown promise in early testing, the biotechnology company reported at the European Society for Medical Oncology Gynaecological Cancers Congress. Zymeworks stock was up more than 1% pre-bell.
Elicio Therapeutics (ELTX) shares were down more than 64% after the company said its Phase 2 clinical study evaluating the experimental pancreatic cancer therapy ELI-002 7p did not meet the pre-specified primary endpoint of disease-free survival.